Cite

HARVARD Citation

    Zhao, Z. et al. (2017). A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer. Medicine. 96 (30), p. . [Online]. 
  
Back to record